dm+d

81088002

New Medicines

Skin and skin structure infections, bone and joint infections, and peri-operative prophylaxis

Information

Generic
Noridem Enterprises + Kent Pharma
Baxter

Development and Regulatory status

Launched
Launched
Launched
Jul 21Cefazolin is also licensed in a number of EU countries, and presumably available for use [5].
Jul 21Available in the UK for treatment of adults, children and infants from the age of 1 month. Given by injection or infusion. Price 1g vials, 10=£161.83; 2g vials, 10=£183.90 [1,4].
Dec 18Licensed by the MHRA for treatment of infections caused by cefazolin-susceptible micro-organisms (skin and soft tissue infections, and bone and joint infections) and perioperative prophylaxis [1].
Oct 17Baxter launched cefazolin in the US as 1 gram cefazolin per 50 mL or 2 gram cefazolin per 100 mL in a single-dose GALAXY containers and supplied as a frozen, premixed, iso-osmotic, sterile, nonpyrogenic solution [2,3].

Category

First-generation cephalosporin initially marketed by GlaxoSmithKline under the trade name Ancef in 1971, and now available as a generic
Skin and soft tissue infections (SSTIs) are common, and complicated SSTIs (cSSTIs) are the more extreme end of this clinical spectrum, encompassing a range of clinical presentations such as deep-seated infection, a requirement for surgical intervention, the presence of systemic signs of sepsis, etc. The vast majority of SSTIs are caused by S. aureus and β-haemolytic streptococci, usually Lancefield groups A, C and G, with group B occurring in diabetics and the elderly.
Skin and skin structure infections, bone and joint infections, and peri-operative prophylaxis
Intravenous injection and
Intravenous infusion